Aquestive Therapeutics Inc (AQST)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Aquestive Therapeutics Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.

Aquestive Therapeutics is a pharmaceutical company developing medicines through innovative delivery technologies as alternatives to invasive therapies. The company advances epinephrine prodrug candidates, including Anaphylm for severe allergic reactions, and operates PharmFilm, an oral film technology platform. Aquestive manufactures four licensed commercialized products for pharmaceutical companies and maintains facilities in Indiana and New Jersey.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Aquestive Therapeutics Inc stock.

Our verdict on AQST

Overvalued: intrinsic value $0.96 per share, market price $3.70, margin of safety -284.6% (as of 2026-11-17).

A 0.6x revenue multiple, discounted for its losses, values the shares at $0.96; the price of $3.70 is 285% above that value.

ETFs with the most weight in AQST

16 more funds hold it; the full list is part of the paid plan.

More on AQST

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than AQST in Drug Manufacturers - Specialty & Generic

28 more in this industry show a wider margin of safety.

Is AQST undervalued or overvalued?

AQST is overvalued (as of the 2026-11-17 close). A 0.6x revenue multiple, discounted for its losses, values the shares at $0.96; the price of $3.70 is 285% above that value.

What is the intrinsic value of AQST?

$0.96 per share (as of the 2026-11-17 close), against a market price of $3.70. That is a margin of safety of -284.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.